Bristol Myers Squibb to Showcase Oncology Pipeline Innovations at ASCO 2026
Event summary
- Bristol Myers Squibb will present data from over 60 disclosures and 19 oral presentations at ASCO 2026, spanning more than 10 cancer types.
- Key data includes late-breaking Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma and Phase 3 data for izalontamab brengitecan in triple-negative breast cancer and esophageal squamous cell carcinoma.
- The company will highlight progress in CELMoD technology, bispecific antibodies, ADCs, and targeted therapies.
- Real-world data on CAR T cell therapy outcomes will also be presented.
The big picture
Bristol Myers Squibb's extensive data presentation at ASCO 2026 underscores its commitment to advancing oncology innovation across multiple tumor types and therapeutic modalities. The focus on CELMoD technology, bispecific antibodies, and ADCs reflects broader industry trends toward targeted and combination therapies. The company's strategic partnerships and real-world evidence initiatives position it to potentially reshape treatment landscapes in hematologic malignancies and solid tumors.
What we're watching
- Pipeline Execution
- Whether Bristol Myers Squibb can translate promising Phase 3 data into regulatory approvals and commercial success for key assets like mezigdomide and izalontamab brengitecan.
- Strategic Partnerships
- The impact of collaborations with BioNTech and Sichuan Biokin on accelerating the development of next-generation oncology therapies.
- Real-World Evidence
- How real-world data on CAR T cell therapies will influence treatment paradigms and reimbursement strategies for cell-based therapies.
Related topics